Systems and methods for remote therapy and patient monitoring are provided. A method comprises contacting an outer skin surface of a patient with a contact surface of a stimulator and transmitting an electrical impulse from the stimulator transcutaneously through the outer skin surface to a nerve within the patient. Data related to parameters of the electrical impulse applied to the nerve is stored and transmitted to a remote source. The data may include duration of treatment, amplitude of the electrical impulse, compliance with a prescribed therapy regimen or other relevant data related to the therapy. The method may further include collecting patient status data, such as symptoms of a medical condition (e.g., severity of a headache) before, during and/or after stimulation. The patient status data is correlated with the treatment data to monitor compliance and/or the effectiveness of the therapy.

Provided herein are methods, devices and compositions for assessing neuromodulation efficacy based on changes in the level of one or more biomarkers in plasma or urine collected from a human subject following a renal neuromodulation procedure.

Equipment for carrying out cardiac autonomic neuropathy tests includes a base unit to which a mouthpiece is connected, forming an autonomous system for measuring the pressure and/or the pattern of breath, provided with a series of LEDs aimed at informing a patient, who is undergoing the test, about correctness or incorrectness of a test execution. The mouthpiece is provided with a flow sensor, aimed at measuring a patient's pattern of breath, and a pressure sensor. The mouthpiece includes also an atmospheric pressure sensor aimed at measuring the environmental pressure. The equipment includes also a sensor, aimed at measuring the heartbeat, applied by simple contact to the patient's wrist area, and an orthostatic measuring device aimed at measuring any change of the patient's position. Data can be introduced or analysed and the type of exam to do can be selected. Results of the tests can be stored in a memory.

A respiratory treatment apparatus (1) provides blood glucose monitoring and breathing control based on detected blood glucose information. In an example embodiment, a flow generator provides a flow of breathable gas at a pressure above atmospheric to a patient interface according to a pressure treatment control protocol such as a CPAP, APAP, bi-level CPAP, etc. A detector determines a blood glucose condition indicator with one or more sensors that are used to sense physiological information. In response to signals from the sensors, a controller, such as a digital signal processor, controls adjustments to the flow of breathable gas provided by the flow generator. The adjustments are determined by the controller based on the detected blood glucose indicator and/or changes thereto.

[Problem] To provide a neurogenic baroreflex sensitivity measurement device, neurogenic baroreflex sensitivity measurement program and neurogenic baroreflex sensitivity measurement method capable of easily and objectively measuring neurogenic baroreflex sensitivity that is not dependent on vascular hardness without using blood pressure or pulsations in the diameter of the carotid artery. [Solution] The neurogenic baroreflex sensitivity measurement device comprises: a pulse wave data-acquiring unit (41) for acquiring pulse wave data of an artery; a normalized pulse wave volume-calculating unit (42) for calculating a normalized pulse wave volume on the basis of the pulse wave data; a pulse interval-acquiring unit (43) for acquiring pulse intervals corresponding to the pulse wave data; a baroreflex series-detecting unit (44) for detecting baroreflex series in which the normalized pulse wave volume and pulse interval both increase or decrease for at least three beats in a row; and a neurogenic baroreflex sensitivity-calculating unit (45) for calculating the slope of a regression line representing the correlation between the normalized pulse wave volume and the pulse interval in a baroreflex series as the neurogenic baroreflex sensitivity, which is an index representing the neurogenic baroreflex function.

An intravascular catheter for nerve activity ablation and/or sensing includes one or more needles advanced through supported guide tubes (needle guiding elements) which expand to contact the interior surface of the wall of the renal artery or other vessel of a human body allowing the needles to be advanced though the vessel wall into the extra-luminal tissue including the media, adventitia and periadvential space. The catheter also includes structures which provide radial and lateral support to the guide tubes so that the guide tubes open uniformly and maintain their position against the interior surface of the vessel wall as the sharpened needles are advanced to penetrate into the vessel wall. Electrodes near the distal ends of the needles allow sensing of nerve activity before and after attempted renal denervation. In a combination embodiment ablative energy or fluid is delivered from the needles in or near the adventitia to ablate nerves outside of the media while sparing nerves within the media.

Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

Methods and systems are provided for monitoring neuromuscular blockade in patients during surgical procedures. In one embodiment, a system includes a stimulator, an electromyography (EMG) sensor, a kinemyography (KMG) sensor, and a single connector configured to couple each of the stimulator, the EMG sensor, and the KMG sensor to a patient monitoring device via a single input. In this way, neuromuscular transmission (NMT) monitoring in patient may be done reliably by ensuring that NMT measurement from a first sensor (EMG sensor) is in line with the measurement of the second sensor (KMG sensor).

An analysis system for analysis of the balance of circadian heart rhythm autonomic nervous system, the analysis system having tools which are designed to perform the following steps after artifact and arrhythmias removal from RR interval series: identification of the chaotic part of the RR interval series and analysis of the chaotic part; separation of the chaotic part from RR interval series and acquisition of the clean circadian RR series; acquisition of the normalized RR interval series using—interpolation, resampling and normalization; analysis of the heart rate bimodal distribution and modes of the normalized RR interval series; identification of the heart rate circadian period in the normalized RR data series; analysis of the heart rhythm variable part SNS and PNS regulation indicators in the normalized RR data series; generation of the report on obtained results in graph and tabular form.

Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.